Trial Profile
An evaluation of the efficacy and safety of PEG-camptothecin [pegamotecan] for second line therapy of locally advanced or metastatic adenocarcinoma of the stomach and gastroesophageal junction
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2005
Price :
$35
*
At a glance
- Drugs Pegamotecan (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 03 Aug 2005 New trial record.